1. Surg Oncol. 2017 Dec;26(4):473-482. doi: 10.1016/j.suronc.2017.09.004. Epub
2017  Sep 21.

ABCB1 gene polymorphisms and response to chemotherapy in breast cancer patients: 
A meta-analysis.

Madrid-Paredes A(1), Cañadas-Garre M(2), Sánchez-Pozo A(3), Expósito-Ruiz M(4), 
Calleja-Hernández MÁ(5).

Author information:
(1)Pharmacogenetics Unit, UGC Provincial de Farmacia de Granada, Instituto de 
Investigación Biosanitaria de Granada, Complejo Hospitalario Universitario de 
Granada, Avda. Fuerzas Armadas, 2, Spain; Department of Biochemistry, Faculty of 
Pharmacy, University of Granada, Campus Universitario de Cartuja, s/n, 18071 
Granada, Spain. Electronic address: adelamadridparedes@gmail.com.
(2)Pharmacogenetics Unit, UGC Provincial de Farmacia de Granada, Instituto de 
Investigación Biosanitaria de Granada, Complejo Hospitalario Universitario de 
Granada, Avda. Fuerzas Armadas, 2, Spain; Queen's University Belfast, Centre for 
Public Health, School of Medicine, Dentistry and Biomedical Sciences, Institute 
of Clinical Sciences, Block B, Royal Victoria Hospital, Grosvenor Road, Belfast 
BT12 6BJ, Northern Ireland, United Kingdom. Electronic address: 
marisacgarre@gmail.com.
(3)Department of Biochemistry, Faculty of Pharmacy, University of Granada, 
Campus Universitario de Cartuja, s/n, 18071 Granada, Spain. Electronic address: 
sanchezpster@gmail.com.
(4)Fundación para la Investigación Biosanitaria de Andalucía Oriental (FIBAO), 
Av. Fuerzas Armadas 2, 1(a)Planta (Biblioteca), 18014 Granada, Spain. Electronic 
address: mexposito@fibao.es.
(5)Pharmacogenetics Unit, UGC Provincial de Farmacia de Granada, Instituto de 
Investigación Biosanitaria de Granada, Complejo Hospitalario Universitario de 
Granada, Avda. Fuerzas Armadas, 2, Spain. Electronic address: 
mangel.calleja.sspa@juntadeandalucia.es.

The ABCB1 gene encodes the P-glycoprotein, an efflux pump for some 
antineoplastic agents which acts as a resistance mechanism to chemotherapy. 
Three SNPs (C3435T, C1236T and G2677T/A), are the most widely studied in ABCB1. 
The inconsistent conclusions about the association of these polymorphisms and 
the response to chemotherapy in breast cancer (BC) patients prompted us to 
conduct a meta-analysis. A total of nine (770 patients), five (566 patients) and 
three studies (367 patients) relating the ABCB1 C3435T, C1236T and G2677T/A 
polymorphisms respectively, were included. The main analysis revealed a lack of 
association between ABCB1 polymorphisms and response to chemotherapy in every 
genetic model: C3435T (dominant OR: 0.888; 95%CI: 0.558-1.413), C1236T (dominant 
OR: 1.968; 95%CI: 0.609-6.362) and G2677T/A (GG vs GT + GA + TT + TA + AA OR: 
0.854; 95%CI: 0.418-1.744). Stratification by ethnicity, cancer type and 
response criteria did not change the pattern of results. The available evidence 
indicates that three polymorphisms within ABCB1; C3435T, C1236T and G2677T/A, 
cannot be considered a reliable predictor of response to chemotherapy in BC 
patients.

Copyright © 2017 Elsevier Ltd. All rights reserved.

DOI: 10.1016/j.suronc.2017.09.004
PMID: 29113667 [Indexed for MEDLINE]